Trial Profile
A Phase II Randomized Double-Blind Trial of Baricitinib or Placebo Combined With Antiviral Therapy in Patients With Moderate and Severe COVID-19
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary) ; Hydroxychloroquine (Primary) ; Lopinavir/ritonavir (Primary) ; Remdesivir (Primary)
- Indications COVID 2019 infections; Respiratory tract infections
- Focus Therapeutic Use
- 21 May 2021 Status changed from recruiting to discontinued.
- 30 May 2020 Planned End Date changed from 24 Apr 2022 to 1 May 2022.
- 30 May 2020 Planned primary completion date changed from 24 Apr 2021 to 1 May 2021.